RCOR

Renovacor, Inc.
RCOR

Delisted

RCOR was delisted on the 30th of November, 2022.

Back to rankings
 

About: Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Employees: 19

Healthcare Drug Manufacturers - General
Charts implemented using Lightweight Charts™